Thera-SAbDab

INEZETAMAB

>   Structural Summary
TherapeuticInezetamab
Target 1CD40
Heavy Chain 1EVQLLESGGGLVQPGGSLRLSCAASGFTFSRNAMSWVRQAPGKGLEWVSATGGSGISTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYSNSWWYFDYWGQGTLVTVSS
Light Chain 1QSALTQPASVSGSPGQSITISCTGTSSDVGNYNLVSWYQQHPGKAPKLMIFEVNQRPSGVSNRFSGSKSGTTASLTISGLQAADEADYFCSSYTTSSTYVIFGGGTKLTVL
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 StructureNone
Target 2MSLN
Heavy Chain 2QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKCLEWISYISSSESIIYYVDAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDVGSHFDYWGQGTLVTVSS
Light Chain 2DIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLISAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQAKSFPRTFGCGTKVEIK
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 StructureNone
>   Metadata
FormatBispecific Mixed mAb and scFv
IsotypeG1;na
Highest Clinical Trial (August '22)TBC
Estimated Status (August '22)Active
Recorded Developmental TechnologyTBC
INN Year Proposed2022
INN Year RecommendedNone
Companies InvolvedTBC
Conditions ApprovedTBC
Conditions ActiveTBC
Conditions DiscontinuedTBC
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy